A. Mackiewicz

发表

Genetically modified dendritic cells – a new, promising cancer treatment strategy?

D. Kowalczyk, P. Wysocki, P. Grabarczyk, 2002, Expert opinion on biological therapy.

Baseline Viral Load and Immune Activation Determine the Extent of Reconstitution of Innate Immune Effectors in HIV-1-Infected Subjects Undergoing Antiretroviral Treatment12

L. Montaner, J. Kostman, K. Mounzer, 2007, The Journal of Immunology.

Subjects Undergoing Antiretroviral Innate Immune Effectors in HIV-1-Infected Determine the Extent of Reconstitution of Baseline Viral Load and Immune Activation

L. Montaner, J. Kostman, K. Mounzer, 2007 .

Gene therapy of cancer

A. Mackiewicz, 1996 .

Double-copy bicistronic retroviral vector platform for gene therapy and tissue engineering: application to melanoma vaccine development

M. Wiznerowicz, R. Hawley, A. Mackiewicz, 1997, Gene Therapy.

Recent developments in renal cell cancer immunotherapy

C. Szczylik, P. Wysocki, A. Mackiewicz, 2007, Expert opinion on biological therapy.

Gene Therapy of Human Melanoma — from Animal Experiments to the Clinical Trial

P. Murawa, J. Malicki, M. Wiznerowicz, 1997 .

Development of a double-copy bicistronic retroviral vector for human gene therapy.

M. Wiznerowicz, R. Hawley, A. Fong, 1998, Advances in experimental medicine and biology.

Flow cytometric cytotoxicity assay with GFP gene modified target cells.

D. Kowalczyk, P. Grabarczyk, D. Iżycki, 2001, Advances in experimental medicine and biology.

IL-6 and GM-CSF in tumor rejection model of renal cell cancer.

D. Kowalczyk, P. Wysocki, P. Grabarczyk, 2001, Advances in experimental medicine and biology.

Effect of irradiation on interleukin 6 and soluble interleukin 6 receptor modified melanoma genetic vaccine

J. Malicki, M. Wiznerowicz, A. Mackiewicz, 1996 .

Improving the retroviral vector (RV) systems for immunotherapy of cancer.

P. Grabarczyk, D. Iżycki, K. Gryska, 2001, Advances in experimental medicine and biology.